Evaluation of efficacy and safety of ibandronate as treatment of metastatic bone pain in patients with different tumor types. A randomised phase II study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-002131-12-IT

Enrollment

Unknown

Registered

2005-08-11

Start date

2005-11-05

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of bone pain in patients with different metastatic tumor types MedDRA version: 6.1 Level: PT Classification code 10027484

Interventions

Trade Name: Bondronat Product Name: NA Product Code: NA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ibandronic acid Concentration unit: mg milligram(s) Concentration type: equal Conce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026